MeSH D016400 - large-cell lymphoma immunoblastic
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Seagen | Brentuximab vedotin | Adcetris | 2011-08-19 | $988.809 M | Q4/22-Q3/23 | |
| Takeda | Brentuximab vedotin | Adcetris | 2012-10-25 |
Clinical Trials
Historical Success Rate
Phase 1
66%33/50
Phase 2
12%6/52
Phase 3
13%1/8
Approved: 1Overall Success rate: 1%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use